Lladó Laura, Fabregat Juan, Castellote José, Ramos Emilio, Torras Jaume, Jorba Rosa, Garcia-Borobia Francisco, Busquets Juli, Figueras Juan, Rafecas Antoni
Department of Surgery, Liver Transplant Unit, H.U. Bellvitge, University of Barcelona, Barcelona, Spain.
Clin Transplant. 2007 Nov-Dec;21(6):716-21. doi: 10.1111/j.1399-0012.2007.00728.x.
Splanchnic thrombosis is a surgical challenge in liver transplantation (LT). The aim of this study was to analyze our experience in the management of portal vein thrombosis, and its influence on evolution.
The aim of this study was to analyze our experience in the management of portal vein thrombosis, and its influence on evolution.
Between 1999 and 2004, 366 liver transplants were performed in 335 patients. Forty-two patients [12.5%: portal vein thrombosis (PVT) group] had portal thrombosis at the time of LT. We analyzed the technical aspects and compared their evolution with a group of patients without portal thrombosis (n = 293; no-PVT group). Retransplantations were excluded.
Of the 42 patients with thrombosis, 18 had partial thrombosis and 16 complete thrombosis [six included the proximal superior mesenteric vein (SMV) and in two the whole splanchnic system]. In 12 cases, usual T-T anastomosis was performed and in 16 cases a thrombectomy was carried out; there were five cases of anastomosis at confluence of the SMV, five cases of anastomosis to a collateral vein, three cases of venous graft, and one case of cavoportal hemitransposition. The operative time was higher in PVT group (417 +/- 103 min vs. 363 +/- 83; p = 0.0005), as RBC transfusion (2.4 +/- 3.1 vs. 1.9 +/- 2.3; p = 0.04), and hospital stay (20.9 +/- 14.9 d vs. 15.1 +/- 10.6; p = 0.002). However, there were no differences in hospital mortality (4% vs. 7.8%; p = 0.98), primary dysfunction (4.8% vs. 7.8%; p = 0.44), or three-yr-actuarial survival (75% vs. 77%; p = 0.95). The incidence of post-transplant thrombosis was higher in the PVT group (15% vs. 2.4%; p = 0.0005).
Portal thrombosis is associated with greater operative complexity and rethrombosis, but has no influence on overall morbidity and mortality.
内脏血栓形成是肝移植(LT)中的一项手术挑战。本研究的目的是分析我们在门静脉血栓管理方面的经验及其对病情发展的影响。
本研究的目的是分析我们在门静脉血栓管理方面的经验及其对病情发展的影响。
1999年至2004年间,对335例患者进行了366例肝移植手术。42例患者[12.5%:门静脉血栓形成(PVT)组]在肝移植时存在门静脉血栓。我们分析了技术方面,并将他们的病情发展与一组无门静脉血栓的患者(n = 293;无PVT组)进行了比较。再次移植的患者被排除在外。
在42例血栓形成患者中,18例为部分血栓形成,16例为完全血栓形成[6例包括肠系膜上静脉(SMV)近端,2例累及整个内脏系统]。12例患者进行了常规的端-端吻合,16例患者进行了血栓切除术;5例在SMV汇合处进行吻合,5例与侧支静脉吻合,3例采用静脉移植,1例采用腔门静脉半转位术。PVT组的手术时间更长(417±103分钟对363±83分钟;p = 0.0005),红细胞输注量更多(2.4±3.1对1.9±2.3;p = 0.04),住院时间更长(20.9±14.9天对15.1±10.6天;p = 0.002)。然而,在医院死亡率(4%对7.8%;p = 0.98)、原发性功能障碍(4.8%对7.8%;p = 0.44)或三年预期生存率(75%对77%;p = 0.95)方面没有差异。PVT组移植后血栓形成的发生率更高(15%对2.4%;p = 0.0005)。
门静脉血栓形成与更高的手术复杂性和再血栓形成相关,但对总体发病率和死亡率没有影响。